A large pharmaceutical company with offices worldwide uses a wide variety of structures in order to engage with innovative early-stage companies, including in-licensing, equity investments, options, collaborations, and acquisitions. The firm is currently looking to form new partnerships with early stage companies worldwide.

The firm is interested in therapeutic assets in the following key disease areas: cardiovascular, fibrosis, immunology, oncology, virology, and genetically-defined diseases. The firm can invest at any stage of development, from very early discovery-stage assets through to marketed products. The firm is open to any technological approach, but is only interested in novel drugs; biosimilars and reformulations are not of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life science dedicated PE fund of a Taiwanese company engaged in leasing, finance, and investment businesses is currently seeking new opportunities. The fund prefers to invest in early stage companies but is also interested in growth-expansion stage companies. The fund can invest up to USD 30 million or more per company. The fund will focus on companies founded and operated in the Greater China region (60% of fund allocation). The fund is also interested in opportunities from Europe (especially in Switzerland, Germany, and the UK) as well as from the US.

The fund seeks to invest in biopharmaceuticals and medical technologies. In biopharma, the fund focuses on novel drugs, drugs with new indication/dosage form, biosimilar, and API for cancer drug. The fund looks for proprietary drug discovery or development technologies that are able to build a multi-product pipeline and products that address large unmet medical needs. For medical technologies, the firm focuses on molecular IVD test/next-generation sequencing, monitor & diagnostics system, invasive devices, cosmetics/plastic surgery, ICT medical device, and combination products with Greater China market potential. The firm looks for new and innovative technologies that can increase performance, lower cost or open up new business models.

The fund prefers to invest in early stage companies and generally acquires a minority stake in the company. However, the fund does not rule out the possibilities of acquiring a controlling stake if the strategic value exists.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A foundation formed to improve the health and quality of life for children has recently begun looking to make equity investment in early stage companies. The foundation’s programs supports pediatric researchers who work in nonprofit academic, medical or research institutions within the six New England states. The foundation is currently developing a new financial vehicle to make program related investment in commercial companies developing technologies that can improve children’s health. The foundation expects to make 1-2 equity allocations of $200,000 in the current year and is seeking opportunities globally.

The foundation is looking for high impact innovations in children’s health with a special interest in neonatal care and pediatric neurology. The foundation is agnostic to technology sectors. The foundation is interested in single assets as well as platform technology that can be applied to the pediatric field.

The foundation seeks privately held companies with competent management teams with sector expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in the Southern United States is currently seeking new investments in healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to invest in syndicates. The firm primarily invests in companies that are based in the Southern U.S. but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, healthcare IT, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company headquartered in Japan is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. The firm is currently looking for partnering and in-licensing opportunities across the globe.

The firm is currently looking for innovative therapeutics targeting cardiovascular-metabolic diseases including obesity, heart failure, metabolic abnormality-induced vascular dysfunction, kidney protection, and stroke. The firm also seeks new treatments for the following indications: sensory neuronal system conditions such as retinal and cochlear degeneration; pain relief through Mu-opioid receptor-dependent and non-opioid mechanisms; immune dysfunctions through mechanisms of homeostatic inflammation, APC, inflammatory factor and B cell function; and fibrosis of lung and the digestive system. However the firm is not interested in the triggers of fibrosis such as inflammation or viral infection. In addition, the firm is interested in muscle atrophy, anemia, and rare/serious diseases.

The firm is looking to partner with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A new corporate VC fund formed by a biopharmaceutical company is looking to invest in life science companies typically at the series A-B stage; initial allocations are generally of about $5 million, with the potential for $10-15 million over the life of an investment. The firm is currently open to opportunities worldwide.

The firm is currently looking to invest in three indication areas: oncology, immunology, and hematology. The fund is technology-agnostic, and is therefore interested in therapeutic, medical device, diagnostic and healthcare IT opportunities in these three areas. The firm is open to investing in companies developing products that have not yet undergone clinical trials, provided that proof of concept data from preclinical studies has been attained (or prototype data in the case of medical devices).

The firm has no set requirements for companies and management teams; applications to the fund are assessed by a triage process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large tech company is currently seeking to invest the in intersection of software and biology. The fund invests in companies at a variety of developmental stages and investments therefore vary widely, but typically range from $1-10m of equity. The firm is looking for opportunities globally.

Within the medical technology sector, the firm is interested in the intersection between communication and health, and particularly in technologies that improve delivery of patient care and make care more cost-effective. Areas of focus include traditional healthcare IT (particularly data and communications in a hospital setting), personalized medicine, mobile health technology (including connected medical devices, consumer apps, and patient monitoring technologies that can be used both inside and outside hospitals), and genomic platforms that provide actionable information for patient care (technologies used purely for gene sequencing are not of interest). While it is not an area of primary focus, connected lab equipment may also be of interest.

The firm invests only in privately-held companies. The firm backs innovative, creative entrepreneurs with expertise in their fields, and who are developing solutions that will have an impact on the health marketplace.If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com